ClinicalTrials.gg

Program

CK-0802

Also written as “CK0801”, “CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)” and “CK0802”.

Its studies are mostly in Bone Marrow Diseases · Graft vs Host Disease · Anemia, Aplastic · Guillain-Barre Syndrome · COVID-19, led by Cellenkos.

Furthest: phase 2, since Mar 24, 20265 company-led studies, 3 open or runningNext primary completion: May 25, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cellenkos53 open or runningphase 2since Mar 24, 2026Oct 23, 2018May 25, 2027phase 1 · NCT03773393

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2018First studies: 2 phase 1 studiesFirst studyNCT03773393, NCT03773328
  2. Jul 10, 2020Phase 1 study in COVID-19NCT04468971 · 45 enrolled · United States
  3. Mar 24, 2026Phase 2 study in Anemia, AplasticPhase 2 reachedNCT07499102 · 12 planned
  4. May 1, 2026Phase 2 study in Graft vs Host DiseaseNCT07576699 · 12 planned

Ahead

  1. May 25, 2027Primary completion: phase 1 study in Bone Marrow DiseasesNCT03773393
  2. Jun 30, 2028Primary completion: phase 2 study in Graft vs Host DiseaseNCT07576699
  3. Aug 3, 2028Primary completion: phase 2 study in Anemia, AplasticNCT07499102

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07576699Graft vs Host Disease2Not yet recruitingJun 30, 202812
NCT07499102Anemia, Aplastic2Not yet recruitingAug 3, 202812
NCT04468971COVID-19 · United States1CompletedOct 22, 202145
NCT03773393Bone Marrow Diseases · United States1Active, not recruitingMay 25, 202718
NCT03773328Guillain-Barre Syndrome1WithdrawnFeb 20250

How it is read

Names in the registry

  • “CK0801”, 3 entries
  • “CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)”, 1 entry
  • “CK0802”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.